ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Aurigene.AI is an end-to-end solution for small molecule drug discovery
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
More than 10,000 scientific publications containing EUDRAGIT
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Subscribe To Our Newsletter & Stay Updated